PATENT COOPERATION TREATY

REC'D 1 3 JUN 2006

	From the INTERNATIONAL SEARCHING AUTHORITY
ĺ	To: JAY Z. ZHANG
	MYRIAD GENETICS, INC.

PCT

JAY Z. ZHANG					
MYRIAD GENETICS, INC.					
320 WAKARA WAY SALT LAKE CITY, UT 84108			WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY		
		INTERNATIO	DNAL SEARCHING AUTHORITY		
			(PCT Rule 43bis.1)		
	_		Date of mailing (day/month/year)	US JUN PAR	
Applicant's or agent's file	reference		FOR FURTHER	FOR FURTHER ACTION See paragraph 2 below	
5062.03WO			(day/month/year) Priority date (day/month/year)		
International application N	0.	International filing date	e (aayimoniniyear)		
PCT/US05/09595		21 March 2005 (21.03.	2005)	19 March 2004 (19.03.2004)	
International Patent Classif					
IPC(7): A61K 31/404; C07	D 209/04 and U	US Cl.: 514/415, 419; 54	18/469, 490, 491		
Applicant					
MYRIAD GENETICE, IN	c				
1. This opinion contains	indications rela	ting to the following ite	ms:		
Box No. I	Basis of the	opinion			
Box No. II	Priority				
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicabi Box No. IV Lack of unity of invention			regard to novelty, inve	ntive step and industrial applicability	
Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement			o novelty, inventive step or industrial internent		
Box No. VI Certain documents cited					
Box No. VII	Box No. VII Certain defects in the international application			·	
Box No. VIII	Certain obse	ervations on the internati	onal application		
2. FURTHER ACTIO	ON			the section of the	
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.					
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.					
	For further options, see Form PCT/ISA/220.				
3. For further details, see	e notes to Form			11 110	
Name and mailing address Mail Stop PCT, A Commissioner for P.O. Box 1450	tn: ISA/US	S Date of comp	pletion of this opinion	Golam M. M. Shameem, Ph.D	
Alexandria, Virgin	nia 22313-1450			Telephone No. (571) 272-1600	

P.O. Box 1450
Alexandria, Virginia 22313-1450
Facsimile No. (703) 305-3230
Form PCT/ISA/237 (cover sheet) (April 2005)

International application No.
PCT/US05/09595

Box No. I Basis of this opinion					
1. With r	1. With regard to the language, this opinion has been established on the basis of:				
	international search (Rules 12.3(a) and 23.1(b)).				
2. With r invent	regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed ion, this opinion has been established on the basis of:				
a.	type of material				
	a sequence listing table(s) related to the sequence listing				
b.	format of material .				
	in electronic form				
c.	time of filing/furnishing				
	contained in the international application as filed.				
	filed together with the international application in electronic form.				
	furnished subsequently to this Authority for the purposes of search.				
3. 🗌	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.				
4. Additional comments:					
	,				
	×				

International application No. PCT/US05/09595

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement 1. Statement			
	en : =		
Inventive step (IS)		YES	
	Ciaima INONE		
Industrial applicability (IA)	Claims 1-9	YES	
	Claims NONE		
2. Citations and explanations:			
Claims 1-9 meet the criteria set out in PCT Article 3 described in this application. The closest prior art of	(2)-(3), because the prior art does accord is US 6,821,997 B1.	not teach or fairly suggest the compounds as	
Claims 1-9 meet the criteria set out in PCT Article 3 claimed can be made or used in industry.		strial applicability because the subject matter	
		·	
		•	
	•		
÷			
		•	

Form PCT/ISA/237 (Box No. V) (April 2005)

]	PATENT COOPERATION TREATY
From the	
INTERNATIONAL SEARCHING AUTHO	PRITY

REC'D 13 JUN 2006

DC	WIPO

PCT

JAY Z. ZHANG MYRIAD GENETICS, INC. 320 WAKARA WAY SALT LAKE CITY, UT 84108		WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY				
				Date of mailing	(PCT Rule 43bis.1)	
				(day/month/year)		
Applicant 5062.03W	's or agent's file i	reference		FOR FURTHER ACTION See paragraph 2 below		
	nal application N	0.	International filing date	(day/month/year)	Priority date (day/month/year)	
PCT/US0:	5/09595		21 March 2005 (21.03.2	005)	19 March 2004 (19.03.2004)	
Internation	nal Patent Classif	ication (IPC) o	or both national classificat			
IPC(7): A	51K 31/404; C07	D 209/04 and I	US Cl.: 514/415, 419; 548	3/469, 490, 491		
Applicant						
MYRIAD	GENETICE, IN	C				
1. This o	pinion contains i	ndications rela	ting to the following item	s:	4.	
	Box No. I	Basis of the	opinion			
	Box No. II	Priority				
	Вох №. ІП	Non-establis	shment of opinion with re	ard to novelty, inventive step and industrial applicability		
Box No. IV Lack of unity of invention						
		.1(a)(i) with regard to novelty, inventive step or industrial as supporting such statement				
Box No. VI Certain documents cited			ments cited		·	
	Box No. VII	Certain defec	ets in the international app	plication		
Box No. VIII Certain observations on the international appli			rvations on the internation	al application		
2. FURT	HER ACTIO	N				
If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.						
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.						
For fur	ther options, see	Form PCT/ISA	V220.			
3. For further details, see notes to Form PCT/ISA/220.						
M	mailing address of	: ISA/US	Date of complet	ion of this opinion	Authorized officer	
P. A	Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450				Golam M. M. Sklafficem, Ph.D/// O	
Facsimile N	acsimile No. (703) 305-3230					

Form PCT/ISA/237 (cover sheet) (April 2005)

⇔.....

To:

International application No.
PCT/US05/09595

Box No. I Basis of this opinion			
1. With regard to the language, this opinion has been established on the basis of:			
the international application in the language in which it was filed			
a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).			
2. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:			
a. type of material			
a sequence listing			
table(s) related to the sequence listing			
b. format of material			
on paper			
in electronic form			
c. time of filing/furnishing			
contained in the international application as filed.			
filed together with the international application in electronic form.			
furnished subsequently to this Authority for the purposes of search.			
3. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.			
4. Additional comments:			
·			

International application No. PCT/US05/09595

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
1. Statement				
Novelty (N)	Claims 1-9	YES		
	Claims NONE	NO		
Inventive step (IS)	Claims 1-9			
	Claims NONE	140		
Industrial applicability (IA)	Claims 1-9	YES		
	Claims NONE	NO		
2. Citations and explanations:				
Claims 1-9 meet the criteria set out in PCT Article 3 described in this application. The closest prior art of	33(2)-(3), because the prior art does not teach or fairl Frecord is US 6,821,997 B1.	y suggest the compounds as		
Claims 1-9 meet the criteria set out in PCT Article 3 claimed can be made or used in industry.	33(4), and thus claims 1-9 have industrial applicabilit	y because the subject matter		
	<u>.</u>			
* .	·			
·	•			
•				
	·			